Log in

Minerva Neurosciences Stock Forecast, Price & News

+0.07 (+2.00 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $3.57
50-Day Range
MA: $3.29
52-Week Range
Now: $3.57
Volume921,736 shs
Average Volume1.58 million shs
Market Capitalization$147.10 million
P/E RatioN/A
Dividend YieldN/A
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Read More
Minerva Neurosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.03 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NERV



Sales & Book Value

Annual SalesN/A
Book Value$0.71 per share


Net Income$-72,180,000.00


Market Cap$147.10 million
Next Earnings Date11/2/2020 (Estimated)
+0.07 (+2.00 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

How has Minerva Neurosciences' stock been impacted by COVID-19?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NERV stock has decreased by 43.9% and is now trading at $3.57.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Minerva Neurosciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Minerva Neurosciences

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Minerva Neurosciences

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences Inc (NASDAQ:NERV) issued its quarterly earnings results on Monday, August, 3rd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $1.02. The biopharmaceutical company earned $41.18 million during the quarter.
View Minerva Neurosciences' earnings history

What price target have analysts set for NERV?

6 analysts have issued 12 month price objectives for Minerva Neurosciences' stock. Their forecasts range from $2.00 to $17.00. On average, they anticipate Minerva Neurosciences' stock price to reach $8.80 in the next twelve months. This suggests a possible upside of 146.5% from the stock's current price.
View analysts' price targets for Minerva Neurosciences

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a drop in short interest during the month of August. As of August 14th, there was short interest totaling 5,350,000 shares, a drop of 17.8% from the July 30th total of 6,510,000 shares. Based on an average trading volume of 3,560,000 shares, the short-interest ratio is presently 1.5 days. Approximately 16.2% of the shares of the stock are short sold.
View Minerva Neurosciences' Short Interest

Who are some of Minerva Neurosciences' key competitors?

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), PTC Therapeutics (PTCT), Immunomedics (IMMU), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Gilead Sciences (GILD), T2 Biosystems (TTOO), Dynavax Technologies (DVAX), Novavax (NVAX) and Moderna (MRNA).

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:
  • Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)
  • Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)
  • Dr. Michael Davidson, Chief Medical Officer (Age 69)
  • Mr. Richard Russell, Pres (Age 55)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 44)

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (3.61%), FMR LLC (3.61%), Artal Group S.A. (1.94%), Goldman Sachs Group Inc. (1.83%), Cormorant Asset Management LP (1.24%) and AQR Capital Management LLC (0.75%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle.
View institutional ownership trends for Minerva Neurosciences

Which institutional investors are selling Minerva Neurosciences stock?

NERV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Artal Group S.A., Nuveen Asset Management LLC, Highland Capital Management Fund Advisors L.P., Cormorant Asset Management LP, UBS Group AG, and Jacobs Levy Equity Management Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, and Remy Luthringer.
View insider buying and selling activity for Minerva Neurosciences

Which institutional investors are buying Minerva Neurosciences stock?

NERV stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., AQR Capital Management LLC, Sei Investments Co., Strs Ohio, Russell Investments Group Ltd., California Public Employees Retirement System, State Board of Administration of Florida Retirement System, and Two Sigma Advisers LP. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, Heek G Jan Van, and William F Doyle.
View insider buying and selling activity for Minerva Neurosciences

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $3.57.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $147.10 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.